|
[1]HAAS JT, FRANCQUE S, STAELS B.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J].Annu Rev Physiol, 2016, 78 (1) :181-205.
|
|
[2]NELSON JE, HANDA P, AOUIZERAT B, et al.Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms[J].Aliment Pharmacol Ther, 2016, 44 (11-12) :1253-1264.
|
|
[3]WU XM.Detection of fatty liver disease in people undergoing physical examination and related factors:an analysis of 867 cases[J].Jilin Med J, 2012, 33 (6) :1154-1155. (in Chinese) 吴晓铭.867例健康体检中脂肪肝检验结果与相关因素分析[J].吉林医学, 2012, 33 (6) :1154-1155.
|
|
[4]ARMSTRONG MJ, HOULIHAN DD, BENTHAM L, et al.Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort[J].J Hepatol, 2012, 56 (1) :234-240.
|
|
[5]CHEN Z, HAN CK, PAN LL, et al.Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects[J].Dig Dis Sci, 2014, 59 (10) :2470-2476.
|
|
[6]MAXIMOS M, BRIL F, SANCHEZ PP, et al.The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease[J].Hepatology, 2015, 61 (1) :153-160.
|
|
[7]CRUZ MA, CRUZ JF, MACENA LB, et al.Association of the nonalcoholic hepatic steatosis and its degrees with the values of liver enzymes and homeostasis model assessment-insulin resistance index[J].Gastroenterology Res, 2015, 8 (5) :260-264.
|
|
[8]BEDOGNI G, BELLENTANI S, MIGLIOLI L, et al.The fatty liver index:a simple and accurate predictor of hepatic steatosis in the generalpopulation[J].BMC Gastroenterol, 2006, 6 (2) :33-38.
|
|
[9]CHAN W K, IDA N H, CHEAH P L, et al.Progression of liver disease in non-alcoholic fatty liver disease:a prospective clinicopathological follow-up study[J].J Dige Dis, 2014, 15 (10) :545-552.
|
|
[10]KAWAMURA Y, IKEDA K, ARASE Y, et al.New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan[J].Hepatol Int, 2015, 9 (2) :269-277.
|
|
[11]LEE JH, KIM D, KIM HJ, et al.Hepatic steatosis index:a simple screening tool reflecting nonalcoholic fatty liver disease[J].Dig Liver Dis, 2010, 42 (7) :503-508.
|
|
[12]KOTRONEN A, PELTONEN M, HAKKARAINEN A, et al.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors[J].Gastroenterology, 2009, 137 (3) :865-872.
|
|
[13]RUFFILLO G, FASSIO E, ALVAREZ E, et al.Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease[J].J Hepatol, 2011, 54 (1) :160-163.
|
|
[14]FALLATAH HI, AKBAR HO, FALLATAH AM, et al.Fibroscan compared to FIB-4, APRI, and AST/ALT ratio for assessment of liver fibrosis in saudi patients with nonalcoholic fatty liver disease[J].Hepat Monm, 2016, 16 (7) :e38346.
|
|
[15]MANOUSOU P, KALAMBOKIS G, GRILLO F, et al.Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients[J].Liver Int, 2011, 31 (5) :730-739.
|
|
[16]KOWDLEY KV, BELT P, WILSON LA, et al.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (1) :77-85.
|
|
[17]MA HM, BAI PP, ZHANG LZ, et al.Change in serum ferritin level and its significance in patients with non-alcoholic fatty liver disease[J].Shandong Med J, 2016, 52 (29) :42-44. (in Chinese) 马会民, 白萍萍, 张连仲, 等.非酒精性脂肪肝患者血清铁蛋白水平变化及意义[J].山东医药, 2016, 52 (29) :42-44.
|
|
[18]FENG HP, REN YL.Signiifcance of serum ferritin in patients with non-alcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :113-115. (in Chinese) 冯红萍, 任艳玲.非酒精性脂肪性肝病患者血清铁蛋白检测的意义[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :113-115.
|
|
[19]GOH GB, ISSA D, LOPEZ R, et al.The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol, 2016, 31 (5) :995-1000.
|
|
[20]HASEGAWA T, TANIGUCHI S, MIHARA M, et al.Toxicity and chemical form of selenium in the liver of mice orally administered selenocystine for 90 days[J].Arch Toxicol, 1994, 68 (2) :91-95.
|
|
[21]KOODZIEJCZYK L, PUT A, GRZELA P, et al.Liver morphology and histochemistry in rats resulting from ingestion of sodium selenite and sodium fluoride[J].Fluoride, 2000, 33:6-16.
|
|
[22]MUELLER AS, KLOMANN SD, WOLF NM, et al.Redox regulation of protein tyrosine phosphatase 1B by manipulation of dietary selenium affects the triglyceride concentration in rat liver[J].J Nutr, 2008, 138 (12) :2328-2336.
|
|
[23]STRANGES S, NAVAS-ACIEN A, RAYMAN MP, et al.Selenium status and cardiometabolic health:state of the evidence[J].Nutr Metab Cardiovasc Dis, 2010, 20 (10) :754-760.
|
|
[24]YANG Z, YAN C, LIU G, et al.Plasma selenium levels and nonalcoholic fatty liver disease in Chinese adults:a cross-sectional analysis[J].Sci Rep, 2016, 6:37288.
|
|
[25]SIROTA J C, MCFANN K, TARGHER G, et al.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States:liver ultrasound data from the National Health and Nutrition Examination Survey[J].Metabolism, 2013, 62 (3) :215-216.
|
|
[26]YUAN H, YU C, LI X, et al.Serum uric acid levels and risk of metabolic syndrome:a dose-response meta-analysis of prospective studies[J].J Clin Endocrinol Metab, 2015, 100 (11) :4198-4207.
|
|
[27]LI SF, LIAO XH, YE JZ, et al.Role of uric acid in the development and progression of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2016, 32 (9) :1814-1818. (in Chinese) 李韶丰, 廖献花, 叶俊钊, 等.尿酸在非酒精性脂肪性肝病发生发展中的作用[J].临床肝胆病杂志, 2016, 32 (9) :1814-1818.
|
|
[28]ZELBERSAGI S, BENASSULI O, RABINOWICH L, et al.The association between serum levels of uric-acid and alanine aminotransferase in a population-based cohort[J].Liver Int, 2015, 35 (11) :s750-s751.
|
|
[29]MASUDA K, NOGUCHI S, ONO M, et al.High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in nonalcoholic fatty liver disease patients before development of diabetes mellitus[J].Hepatol Res, 2016.[Epub ahead of print]
|
|
[30]GRAHAM TE, YANG Q, BLUHER M, et al.Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects[J].N Engl J Med, 2006, 354 (24) :2552-2563.
|
|
[31]SUN LS, FAN LY, WANG N, et al.The correlation between serum RBP-4 and nonalcoholic fatty liver disease[J].Lab Med, 2011, 26 (9) :602-605. (in Chinese) 孙立山, 范列英, 王暖, 等.血清视黄醇结合蛋白4和非酒精性脂肪性肝病的相关性[J].检验医学, 2011, 26 (9) :602-605.
|
|
[32]CHANG X, YAN H, BIAN H, et al.Serum retinol binding protein4 is associated with visceral fat in human with nonalcoholic fatty liver disease without known diabetes:a cross-sectional study[J].Lipids Health Dis, 2015, 14:28.
|
|
[33]LIU Y, MU D, CHEN H, et al.Retinol-binding protein 4 induces hepatic mitochondrial dysfunction and promotes hepatic steatosis[J].J Clin Endocrinol Metab, 2016, 101 (11) :4338-4348.
|
|
[34]MALIKEN BD, NELSON JE, KLINTWORTH HM, et al.Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease[J].Hepatology, 2013, 57 (5) :1806-1813.
|
|
[35]CASTERA L, VILGRAIN V, ANGULO P.Noninvasive evaluation of NAFLD[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :666-675.
|
|
[36]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J].Gastroenterology, 2012, 142 (7) :15921-609.
|
|
[37]KAZANKOV K, BARRERA F, MØLLER HJ, et al.The macrophage activation marker s CD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease[J].Liver Int, 2016, 36 (10) :1549-1557.
|
|
[38]FELDSTEIN AE, ALKHOURI N, DE VR, et al.Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children[J].Am J Gastroenterol, 2013, 108 (9) :1526-1531.
|
|
[39]LI N, ZHOU MJ, CHEN N.Expression and significance of serum TNF-αand CK-18 levels in children with non-alcoholic steatohepatitis[J].Chin Gen Pract, 2014, 17 (15) :1723-1727. (in Chinese) 李娜, 周明锦, 陈楠.非酒精性脂肪性肝炎患儿血清肿瘤坏死因子α与细胞角质蛋白18的表达及意义研究[J].中国全科医学, 2014, 17 (15) :1723-1727.
|
|
[40]ZWOLAK A, SZUSTER-CIESIELSKA A, DANILUK J, et al.Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease[J].Ann Hepatol, 2016, 15 (6) :862-869.
|
|
[41]KADOWAKI T, YAMAUCHI T.Adiponectin and adiponectin receptors.[J].Endocrine Reviews, 2005, 26 (3) :439-451.
|
|
[42]POLYZOS SA, TOULIS KA, GOULIS DG, et al.Serum total adiponectin in nonalcoholic fatty liver disease:a systematic review and meta-analysis[J].Metabolism, 2011, 60 (3) :313-326.
|
|
[43]LAN CM.Measurements of tumor necrosis factor-αand interleukin-6 and their significance in patients with varying degrees of nonalcoholic fatty liver disease[J].Mod Digest Interv, 2016, 21 (1) :85-87. (in Chinese) 蓝常明.不同程度非酒精性脂肪肝患者肿瘤坏死因子-α、白介素-6的检测及意义[J].现代消化及介入诊疗, 2016, 21 (1) :85-87.
|
|
[44]SEVERSON TJ, BESUR S, BONKOVSKY HL.Genetic factors that affec nonalcoholic fatty liver disease:a systematic clinical review.[J].World JGastroenterol, 2016, 22 (29) :6742-6756.
|
|
[45]KRAWCZYK M, RAU M, SCHATTENBERG JM, et al.Combined effects of the TM6SF2 rs58542926, PNPLA3 rs738409 and MBOAT7 rs641738 variants on NAFLD severity:multicentre biopsy-based study[J].J Lipid Res, 2017, 58 (1) :247-255.
|
|
[46]SEKO Y, SUMIDA Y, TANAKA S, et al.Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease:association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression[J].Hepatol Res, 2016.[Epub ahead of print]
|
|
[47]KOZLITINA J, SMAGRIS E, STENDER S, et al.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2014, 46 (4) :352-356.
|
|
[48]WANG X, LIU Z, WANG K, et al.Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population[J].Front Genet, 2016, 7:140.
|
|
[49]KRAWCZYK M, RAU M, SCHATTENBERG J, et al.Combined effects of the prosteatotic TM6SF2 and PNPLA3 variants on severity o NALFD:multicentre biopsy-based study in German patients[J].ZGastroenterol, 2015, 53 (12) :1391-1602.
|
|
[50]CAI T, DUFOUR JF, MUELLHAUPT B, et al.Viral genotypespecifi c role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis[J].J Hepatol, 2011, 55 (3) :529-535.
|
|
[51]ABE H, OCHI H, MAEKAWA T, et al.Common variation of IL28affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients[J].J Hepatol, 2010, 53 (3) :439-443.
|
|
[52]MARABITA F, AGHEMO A, de NICOLA S, et al.Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection[J].Hepatology, 2011, 54 (4) :1127-1134.
|
|
[53]PETTA S, GRIMAUDO S, CAMMA C, et al.IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease[J].J Hepatol, 2012, 56 (6) :1356-1362.
|
|
[54]PETTA S, CRAXI A.Reply to:“IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients”[J].J Hepatol, 2013, 58 (2) :403-404.
|
|
[55]GARRETT ME, ABDELMALEK MF, ASHLEY-KOCH A, et al.IL28B rs12979860 is not associated with histologic features of NAFLDin a cohort of Caucasian North American patients[J].J Hepatol, 2013, 58 (2) :402-403.
|
|
[56]HASHEMI M, MOAZENI-ROODI A, BAHARI A, et al.A tetra-primer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype[J].Nucleosides Nucleotides Nucleic Acids, 2012, 31 (1) :55-60.
|
|
[57]LI JW.Association between polymorphisms of rs12979860 and rs8099917 in IL28B gene and non-alcoholic fatty liver disease[D].Dalian:Dalian Med Univ, 2015. (in Chinese) 李江文.IL28B基因rs12979860、rs8099917多态性与NAFLD的相关性研究[D].大连:大连医科大学, 2015.
|
|
[58]POYNARD T, RATZIU V, NAVEAU S, et al.The diagnostic value of bio-markers (Steato Test) for the prediction of liver steatosis[J].Comp Hepatol, 2005, 4 (23) :10-17.
|
|
[59]BEDOGNI G, KAHN HS, BELLENTANI S, et al.A simple index of lipidoveraccumulation is a good marker of liver steatosis[J].BMC Gas-troenterol, 2010, 10 (25) :98-104.
|
|
[60]LYKIARDOPOULOS B, HAGSTROM H, FREDRIKSON M, et al.Development of serum marker models to increase diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease:the new LIN-KI algorithm compared with established algorithms[J].PLo S One, 2016, 11 (12) :e0167776.
|
|
[61]FAN JG.Research advances in non-alcoholic fatty liver disease:a review of current status and prospect[J].J Clin Hepatol, 2015, 31 (7) :999-1001. (in Chinese) 范建高.非酒精性脂肪性肝病的研究现状与展望[J].临床肝胆病杂志, 2015, 31 (7) :999-1001.
|
DownLoad: